Biofrontera Inc (BFRI) Quote

4 hour RSI Relative Strength Index 22.85. Market cap 3.9 Million


FDA approved drug with 13 Million patient market place and best in class RX for Ameluz®-PDT is indicated for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions. Biofrontera also commercializes the drug Xepi® (ozenoxacin cream, 1%), FDA-approved for the treatment of impetigo.

News on the approval for 3 Tubes instead of 1 for a treatment is a big deal!


WOBURN, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”) , a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s sNDA to increase the maximally approved dosage from one to three tubes of Ameluz ® per treatment.

BFRI Pipeline
https://www.biofrontera-us.com/research/product-pipeline

BF-200 ALA AK: Pharmacokinetics study Completed
BF-200 ALA AK: Safety study for use of 3 tubes ♦ Completed & Approved
BF-200 ALA Superficial basal cell carcinoma ♦ Last patient in Phase 3 (HUGE)
BF-200 ALA Moderate to severe acne ♦ Phase II ongoing. (massive market)
BF-200 ALA AK: Face and scalp with pain-reducing illumination protocol Phase III in preparation. (Niche Market)
BF-200 ALA AK: Trunk & extremities ♦ Phase III ongoing (key segment in skin disorders)
BF-200 ALA Squamous cell carcinoma in situ Phase III in preparation. (Billion dollar market)

This company can move a 1000% a still be undervalued. Roth analyst gave a $16.00 Target this week. Cash flow positive in 2025

Almost 60% shares locked up by insiders and Institutions 35 million in sales 34% YOY growth and 3 Tubes approval this week.


$BFRI

Sponging up shares RSI is extremely oversold!

Buy the fear and make the big $

$ 4 Million Micro cap with FDA approved skin cancer drugs with a deep late stage pipeline!


$BFRI

13 million patients for Ameluz® (aminolevulinic acid hydrochloride)
Topical gel, $1200 for 3 tubes 1st Line Best in class topical only one other drug on the market that has side effects and less effective.

“Up to 60% of squamous cell carcinomas begin as untreated AK lesions, so it’s important for us to be able to treat the entire affected field. I have used Ameluz ® now for more than 7 years for the management of AK because of the demonstrated efficacy and safety it delivers. With the approval of the sNDA, I look forward to being able to use up to three tubes for those patients that need them,” said Dr. Jonathan Weiss, investigator and co-managing partner at Georgia Dermatology Partners in Atlanta.

https://www.biofrontera-us.com/research/product-pipeline

Nearly 60% of the shares held by insiders and institutions revenues should drastically increase from the $1200 cost of 3 tubes the FDA has approved in a singles use compared to 1 tube which ran about $400.00

ROTH gave a $16.00 price target a few days ago Cash flow positive coming quarters!
3 days ago — Roth/MKM analyst Jonathan Aschoff reiterated a Buy rating and $16.00 price target on Biofrontera (NASDAQ: BFRI).

$5.00 gap fill then $10.00+ Way Oversold on the RSI

$50 Million market is in line with their sales and massive growth + pipeline that will be seen in the coming quarters cash flow positive near team. 5 million market cap today.

$BFRI

Ameluz Skin Cancer Prevention prescription +PDT (Photodynamic Therapy)


Micro Float of 2.5 Million I own a decent chunk of the floating shares and will keep adding.

5 Million market cap.

Cash flow positive in the coming quarters deep late stage pipeline with multiple approved FDA drugs.

https://www.biofrontera-us.com/research/product-pipeline

Roth/MKM analyst Jonathan Aschoff reiterated a Buy rating and $16.00 price target on Biofrontera (NASDAQ: BFRI)
https://www.streetinsider.com/Analyst+Comments/RothMKM+Reiterates+Buy+Rating+on+Biofrontera+%28BFRI%29/23809849.html

$BFRI

Multiple suitors looking to acquire This is going to be funny when the buyout is announced!

The late stage pipeline has some very spectacular molecules for skin disease. Profitable Next Year!

Added 71k today on the fake red candle. Going to get aggressive here. Bears are going to get a sharp stick in the eye!


$BFRI

10x is possible here debt scrubbed profitable next year New Board member who is the largest shareholder

2 Million share float insiders and Tutues are up to 57% now



BFRI drug that just got approved for 3 tubes instead of 1 tube for their drug Ameluz

Estimated 13 million treatments given each year.

Each dose of Ameluz 10% topical gel is around $392.

Maximum dosage units is approximately $1,176.

That's a potential of 10 million additional units per treatment.


BF-200 ALA AK: Pharmacokinetics study Completed
BF-200 ALA AK: Safety study for use of 3 tubes ♦ Completed
BF-200 ALA Superficial basal cell carcinoma ♦ Last patient in
BF-200 ALA Moderate to severe acne ♦ Phase II ongoing
BF-200 ALA AK: Face and scalp with pain-reducing illumination protocol Phase III in preparation
BF-200 ALA AK: Trunk & extremities ♦ Phase III ongoing
BF-200 ALA Squamous cell carcinoma in situ Phase III in preparation

$BFRI

BFRI............................https://stockcharts.com/h-sc/ui?s=BFRI&p=W&b=5&g=0&id=p86431144783

BFRI. Under $2

BFRI..............................https://stockcharts.com/h-sc/ui?s=BFRI&p=W&b=5&g=0&id=p86431144783

BFRI under $2

BFRI under $2

BFRI...............................................https://stockcharts.com/h-sc/ui?s=BFRI&p=W&b=5&g=0&id=p86431144783

awaiting pop from pp closing,restructure gives new hope,accumulation started fri,shares to short 60k(watching for decline)

This is what's really happing in the news:)

https://www.accesswire.com/viewarticle.aspx?id=835060

BFRI: Nice trick!!! (WOW, these firms are CLEVER!!!)

That was quick

Boom

Form RW - Registration Withdrawal Request

We trading baby!!

BFRI$ Bullish

BFRI new 52 week low

BFRI new 52 week low

BFRI new 52=week low

BFRI new 52 week low

Word on the street is that BFRI is restructuring… laid off a significant number of sales reps today

BFRI new 52 week low

BFRI new 52 week low

I would stay away from this stock. If you do your due diligence Biofrontera (AG) & Inc in 25+ years have never turned a profit. Looking at BF AG …5/6 years ago the market cap was over $300 million. Look now at the combined market cap of Inc & AG. It’s a small fraction of that. Further, if you look at the Actinic Keratosis market and the players. The competitor dominates, other modalities are preferable. BF Inc would need $100 million minimum to get to profitability… and even then I don’t think it would. BF has raised about a quarter billion in 25+ years and still can’t turn a profit. It was recently announced that 2 investors bailed. My guess is that you will lose your shirt and everything else with this company. It’s poorly run!

BFRI new 52 week low

What’s the deal

LETS SEE 80C

BFRI...BIO BEAST!

Only up 30 to 40% premarket

Crazy right

$BFRI is up 60% after hours on no news.

https://www.marketscreener.com/quote/stock/BIOFRONTERA-INC-128192403/news/BIOFRONTERA-INC-Notice-of-Delisting-or-Failure-to-Satisfy-a-Continued-Listing-Rule-or-Standard-T-43135289/

Dead!!!

So quiet here these days. BFRI

Next chance mid October imo, the 13th

Definitely would want the share price to increase to its appropriate mean level (6.00 imo) to ease the pressure of the 87,000 IRS agents looking into movement of prices and the reasoning thereof, now that it appears the company was bought out getting back to a normal Shareprice could be a financial priority.

BFRI - 2 Friday

The last time a Friday was the 2nd day of the month was July 2, 2021. BFRI opened for trading October 29, 2021.

5 day consolidation completes in 5 minutes

If the share price would rise it would be now if the takeover is completed no need to decrease the price further

My guess could be these guys since they already have a nice chuck of this...

Japan's Maruho Co. Ltd. 29.99% stake.

Adding up all the shares from each entity mentioned in the form 13 collectively, since all the entities appear to be interconnected and on the same side of the legal dispute, is still about 37.5 percent of 56 million in my estimation,

The below page lists Zours as current chairman of BFRI:

https://people.equilar.com/bio/wilhelm-zours-biofrontera-ag/33831858

The company could clarify:

Who is in control of the company and by what method was the OS increased.

That's based on 25,500,950 o/s.

Now it's 56,717,385 o/s.

They don't own majority anymore.

The chairman of BFRI is also the head of DB, I think the takeover already happened.

You're totally right about the increase in the O/S. My guess is that someone what's to take control of the company, other than the guy who's buying up shares currently. Maybe a poison pill is in the works?

The link content is in German I think and I am not going to translate it because I don’t understand how the outstanding shares increased to 56 million, as referenced in the form 13.

Have you reviewed the results of the shareholders meeting? Can't post link, but it's on the company website.